Neurogene Inc. Gain (Loss) on Termination of Lease
Neurogene Inc. (NGNE) reported Gain (Loss) on Termination of Lease of -$300.00 thousand for the 9-month period ending 2020-09-30, per its 10-Q filed 2021-11-04.
Discontinued › Income Statement › Other Income
us-gaap:GainLossOnTerminationOfLease · last filed 2022-03-01
- 2020-09-30: Gain (Loss) on Termination of Lease 9 month -$300.00K.
- 2020-06-30: Gain (Loss) on Termination of Lease -$300.00K; Gain (Loss) on Termination of Lease 1 month -$300.00K.
| Period end | Gain (Loss) on Termination of Lease | Gain (Loss) on Termination of Lease 1 month | Gain (Loss) on Termination of Lease 9 month |
|---|---|---|---|
| 2020-09-30 | -$300.00K 10-Q · filed 2021-11-04 | ||
| 2020-06-30 | -$300.00K 10-K · filed 2021-03-25 | -$300.00K 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |